Welcome to our dedicated page for Clearside Biomedical news (Ticker: CLSD), a resource for investors and traders seeking the latest updates and insights on Clearside Biomedical stock.
Clearside Biomedical, Inc. (symbol: CLSD) is a prominent clinical biopharmaceutical company based in Alpharetta, Georgia. Specializing in the development of pharmacological therapies, the company's primary focus is on treating blinding diseases of the eye through their innovative suprachoroidal space (SCS) technology.
Clearside Biomedical's cornerstone is their SCS Microinjector®, a proprietary device that facilitates a non-surgical, office-based procedure. This technology allows for targeted delivery of therapies directly to the macula, retina, or choroid, which could potentially preserve and enhance vision for patients suffering from severe eye conditions.
One of the company's significant achievements is the robust safety profile and encouraging efficacy data from multiple studies using the SCS Microinjector®. These findings have been featured in numerous oral and poster presentations, highlighting the potential of Clearside’s technology in ophthalmic therapeutics.
Clearside Biomedical continues to advance its pipeline of ophthalmic therapies, collaborating with various partners to bring innovative treatments to market. The company remains committed to improving the quality of life for individuals with vision-threatening diseases through groundbreaking research and development.
Recent Achievements:
- Clinical data utilizing Clearside’s suprachoroidal delivery technology featured in multiple presentations.
- Enhanced safety and efficacy data presented, showcasing the utility of the SCS Microinjector®.
Investors and media can reach out to Jenny Kobin and Remy Bernarda for more information at ir@clearsidebio.com or by calling (678) 430-8206.
Clearside Biomedical, a biopharmaceutical company focused on vision restoration treatments, will present a company overview at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 8:40 a.m. ET. The presentation will be accessible via a live webcast on the Clearside website, with an archived version available for three months. Clearside specializes in innovative approaches to treat serious back of the eye diseases using their proprietary SCS Microinjector technology, which allows targeted delivery of treatments.
Clearside Biomedical (NASDAQ:CLSD) announced the initiation of a Phase 1/2a trial for CLS-AX aimed at treating wet age-related macular degeneration (AMD) by year-end 2020. The company reported Q3 2020 financial results, showing license revenue of $3.4 million, a significant increase from $141,000 in Q3 2019, mainly due to a partner milestone payment. Research expenses rose to $3.5 million, partly due to preparations for CLS-AX, while the net loss decreased to $2.4 million, or $0.05 per share. Clearside expects to have sufficient resources to fund operations into Q3 2021.
Clearside Biomedical (NASDAQ:CLSD) will report its third quarter 2020 financial results on November 10, 2020, after market close. A webcast and conference call are scheduled for 4:30 PM ET for discussions on these results and corporate updates. Clearside specializes in treatments aimed at restoring vision for patients with serious eye diseases, utilizing a flexible, non-surgical SCS Microinjector® to deliver targeted therapies.
Clearside Biomedical (Nasdaq: CLSD) announced clinical data presentations at the 53rd Annual Scientific Meeting of The Retina Society, highlighting its investigational drug, XIPERE™, in a Phase 2 trial for diabetic macular edema (DME). The trial suggests XIPERE may reduce treatment burden if approved. The company also plans to initiate a Phase 1/2a trial for CLS-AX in wet AMD this year. Data presented includes positive tolerability results for CLS-AX and promising outcomes for suprachoroidal injections, potentially establishing Clearside's innovative approach in retinal disease therapies.
Clearside Biomedical (NASDAQ:CLSD) announced that its leadership team, including President George Lasezkay and CMO Thomas Ciulla, will provide a company overview at the Virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 11:30 a.m. ET. The presentation will focus on Clearside's innovative treatments aimed at restoring vision for individuals with serious back-of-the-eye diseases. Interested parties can access the live and archived webcast through the company's website under the Investors section for three months.
Clearside Biomedical (NASDAQ: CLSD) announced the issuance of three additional patents in the U.S. and Europe, bolstering its intellectual property portfolio, particularly for the SCS Microinjector. The U.S. Patent No. 10,722,396, expiring in 2034, covers the administration of axitinib. European patents include one for a device for therapeutic administration, expiring in 2031, and another for XIPERE™ treatment, expiring in 2033. With 21 U.S. and 20 European patents, Clearside aims to advance its pipeline, including three product candidates anticipated in clinical trials by year-end.
Clearside Biomedical (NASDAQ:CLSD) reports key updates and financial results for Q2 2020. The FDA accepted its IND application for CLS-AX (axitinib injectable suspension), marking a significant step in its suprachoroidal pipeline expansion. Clearside initiated two new preclinical programs and partnered with a new manufacturer for XIPERE, enhancing production efficiency. Despite a net loss of $5.8 million for Q2, up from $5.7 million, the company believes it has adequate cash resources to sustain operations until mid-2021, supported by its licensing revenue growth to $0.4 million.
Clearside Biomedical (Nasdaq: CLSD) announced that the FDA has accepted its IND application for CLS-AX, allowing the initiation of a Phase 1/2a clinical trial for wet AMD patients by year-end 2020. CLS-AX is a proprietary axitinib injectable suspension aimed at providing a long-acting treatment option. The trial will evaluate the safety and tolerability of CLS-AX via suprachoroidal injection after prior anti-VEGF treatments. This milestone reflects Clearside's progress in addressing significant needs within the ophthalmology market.
Clearside Biomedical (NASDAQ: CLSD) will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 9:10 a.m. ET. George Lasezkay, Pharm.D., J.D., CEO, and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer, will lead the presentation. A live and archived webcast will be accessible on the Clearside website for three months. Clearside is focused on innovative treatments for serious back of the eye diseases, utilizing its proprietary SCS Microinjector™ for targeted medication delivery.
Clearside Biomedical (CLSD) will report its Q2 2020 financial results on August 10, 2020, after market close. A conference call with management is set for 4:30 PM ET to discuss the results and provide updates. The company focuses on treatments targeting serious eye diseases using its proprietary SCS Microinjector®, facilitating targeted delivery of medications. This innovative technology aims to restore and preserve vision, directly addressing sight-threatening conditions.
FAQ
What is the current stock price of Clearside Biomedical (CLSD)?
What is the market cap of Clearside Biomedical (CLSD)?
What does Clearside Biomedical, Inc. specialize in?
Where is Clearside Biomedical, Inc. located?
What is the SCS Microinjector®?
How does Clearside Biomedical's technology benefit patients?
What recent achievements has Clearside Biomedical reported?
Who can be contacted for investor and media inquiries?
What kind of presentations feature Clearside's technology?
What diseases is Clearside Biomedical targeting with their therapies?
Is Clearside Biomedical's procedure surgical?
What is the significance of Clearside's technology in ophthalmology?
